The Journal of Experimental Medicine
Aegean Conferences: 2009 Conferences
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online 24 September 2001. doi:10.1084/jem.194.7.873
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 176K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McQualter, J. L.
Right arrow Articles by Bernard, C. C.A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McQualter, J. L.
Right arrow Articles by Bernard, C. C.A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© The Rockefeller University Press, 0022-1007/2001/10/873/ $5.00
The Journal of Experimental Medicine, Volume 194, Number 7, October 1, 2001 873-882

Original Article

Granulocyte Macrophage Colony-stimulating Factor: A New Putative Therapeutic Target in Multiple Sclerosis

Jonathan L. McQualtera, Rima Darwicheb, Christine Ewinga, Manabu Onukia, Thomas W. Kayb, John A. Hamiltonc, Hugh H. Reida, and Claude C.A. Bernarda
a Neuroimmunology Laboratory, Department of Biochemistry, La Trobe University, Victoria 3086, Australia
b Autoimmunity and Transplantation Division, The Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital,
c Arthritis and Inflammation Research Center, Department of Medicine, University of Melbourne, Royal Melbourne Hospital, Melbourne, Victoria 3050, Australia

Correspondence to: Claude C.A. Bernard, Neuroimmunology Laboratory, Dept. of Biochemistry, La Trobe University, Victoria 3086, Australia. Tel:61-3-9479-2149 Fax:61-3-9479-2467 E-mail:c.bernard{at}latrobe.edu.au.

Experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis, can be induced by immunization with a number of myelin antigens. In particular, myelin oligodendrocyte glycoprotein, a central nervous system (CNS)-specific antigen expressed on the myelin surface, is able to induce a paralytic MS-like disease with extensive CNS inflammation and demyelination in several strains of animals. Although not well understood, the egress of immune cells into the CNS in EAE is governed by a complex interplay between pro and antiinflammatory cytokines and chemokines. The hematopoietic growth factor, granulocyte macrophage colony-stimulating factor (GM-CSF), is considered to play a central role in maintaining chronic inflammation. The present study was designed to investigate the previously unexplored role of GM-CSF in autoimmune-mediated demyelination. GM-CSF-/- mice are resistant to EAE, display decreased antigen-specific proliferation of splenocytes, and fail to sustain immune cell infiltrates in the CNS, thus revealing key activities for GM-CSF in the development of inflammatory demyelinating lesions and control of migration and/or proliferation of leukocytes within the CNS. These results hold implications for the pathogenesis of inflammatory and demyelinating diseases and may provide the basis for more effective therapies for inflammatory diseases, and more specifically for multiple sclerosis.

Key Words: multiple sclerosis, experimental autoimmune encephalomyelitis, GM-CSF, myelin oligodendrocyte glycoprotein, immune therapy


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS